National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments
22 mars 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
64% of adults with plaque psoriasis who are on topical treatments reported ever having psoriasis in intertriginous areas, higher than previous epidemiological studies suggestAround three in four...
Arcutis to Host Investor Day on March 28
21 mars 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 mars 2022 16h05 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Present at Upcoming Investor Conference
02 mars 2022 05h30 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
22 févr. 2022 16h01 HE
|
Arcutis Biotherapeutics, Inc.
Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment...
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
01 févr. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023A total of 457 subjects are enrolled in the STRATUM studySeborrheic dermatitis affects 10...
Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
23 déc. 2021 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
22 déc. 2021 16h01 HE
|
Arcutis Biotherapeutics, Inc.
FDA has set a target action date of July 29, 2022NDA supported by positive efficacy data from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety...
Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary
16 déc. 2021 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Present at Upcoming Investor Conference
10 nov. 2021 08h02 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...